Long-term outcomes of local resection versus surgical resection for high-risk T1 colorectal cancer: a systematic review and meta-analysis

医学 危险系数 结直肠癌 置信区间 内科学 生存分析 淋巴结 荟萃分析 比例危险模型 肿瘤科 胃肠病学 癌症 外科
作者
Yuxiang Chen,Weina Jing,Mo Chen,Zhu Wang,Junchao Wu,Jinlin Yang,Yang Li,Kai Deng
出处
期刊:Gastrointestinal Endoscopy [Elsevier BV]
卷期号:97 (6): 1016-1030.e14 被引量:19
标识
DOI:10.1016/j.gie.2023.02.027
摘要

Patients with T1 colorectal cancer (CRC) are at high risk for lymph node metastasis and recurrence after local resection (LR) and need surgical resection (SR) for additional lymph node dissection to improve prognosis. However, the net benefits of SR and LR are still unquantified.We conducted a systematic search for studies in which survival analysis among high-risk T1 CRC patients undergoing LR and SR was performed. Overall survival (OS), recurrence-free survival (RFS), and disease-specific survival (DSS) data were extracted. Hazard ratios (HRs) and fitted survival curves for OS, RFS, and DSS were used to estimate the long-term clinical outcomes of patients in the 2 groups.This meta-analysis included 12 studies. Compared with those in the SR group, patients in the LR group had higher risks of death (HR, 2.06; 95% confidence interval [CI], 1.59-2.65), recurrence (HR, 3.51; 95% CI, 2.51-4.93), and cancer-related mortality (HR, 2.31; 95% CI, 1.17-4.54) in the long term. Fitted survival curves for the LR and SR groups revealed the 5-year, 10-year, and 20-year rates for OS (86.3% and 94.5%, 72.9% and 84.4%, and 61.8% and 71.1%), RFS (89.9% and 96.9%, 83.3% and 93.9%, and 29.6% and 90.8%), and DSS (96.7% and 98.3%, 86.9% and 97.1%, and 86.9% and 96.4%). Log-rank tests showed significant differences among all outcomes except 5-year DSS.For high-risk T1 CRC patients, the net benefit of DSS appears to be significant when the observation period exceeds 10 years. A long-term net benefit may exist but may not be applicable to all patients, especially high-risk patients with comorbidities. Therefore, LR may be a reasonable alternative for individualized treatment for some high-risk T1 CRC patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
yww发布了新的文献求助10
刚刚
思源应助维克托采纳,获得10
刚刚
David梁生完成签到 ,获得积分10
刚刚
wz关闭了wz文献求助
刚刚
1秒前
1秒前
简单花花发布了新的文献求助10
2秒前
Dongao发布了新的文献求助10
4秒前
weiiioyo发布了新的文献求助10
4秒前
5秒前
埋土人完成签到,获得积分10
7秒前
科研小卡拉米完成签到,获得积分10
7秒前
烟花应助全佳伟采纳,获得10
7秒前
大模型应助淮上有秋山采纳,获得10
8秒前
Garnieta完成签到,获得积分10
8秒前
ChenXuan完成签到,获得积分10
8秒前
JJ完成签到,获得积分10
9秒前
guan完成签到,获得积分10
10秒前
11秒前
11秒前
12秒前
朴实千筹完成签到,获得积分10
12秒前
杨111完成签到,获得积分10
13秒前
14秒前
14秒前
yzkistudy发布了新的文献求助10
15秒前
16秒前
Zeze完成签到,获得积分10
16秒前
曦和完成签到,获得积分10
16秒前
SEAL发布了新的文献求助10
17秒前
海盗完成签到,获得积分10
17秒前
17秒前
王术发布了新的文献求助10
18秒前
Owen应助科研通管家采纳,获得30
18秒前
搜集达人应助科研通管家采纳,获得10
18秒前
充电宝应助科研通管家采纳,获得10
19秒前
chenwei发布了新的文献求助10
19秒前
Jasper应助科研通管家采纳,获得10
19秒前
乐乐应助XX采纳,获得10
19秒前
无极微光应助科研通管家采纳,获得20
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Picture this! Including first nations fiction picture books in school library collections 2000
The Cambridge History of China: Volume 4, Sui and T'ang China, 589–906 AD, Part Two 1500
Cowries - A Guide to the Gastropod Family Cypraeidae 1200
Quality by Design - An Indispensable Approach to Accelerate Biopharmaceutical Product Development 800
ON THE THEORY OF BIRATIONAL BLOWING-UP 666
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6390993
求助须知:如何正确求助?哪些是违规求助? 8206066
关于积分的说明 17368477
捐赠科研通 5444620
什么是DOI,文献DOI怎么找? 2878676
邀请新用户注册赠送积分活动 1855152
关于科研通互助平台的介绍 1698381